title: Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.
abstract: Quetiapine is an established drug for treatment of schizophrenia, bipolar disorder, and major depressive disorder. While initially manufactured as an immediate-release (IR) formulation, an extended-release (XR) formulation has recently been introduced. Pharmacokinetic studies show that quetiapine XR provides a lower peak and more stable plasma concentration than the IR formulation. This study investigated if the pharmacokinetic differences translate into different time curves for central D₂ dopamine receptor occupancy. Eleven control subjects were examined with positron emission tomography (PET) and the radioligand [11C]raclopride. Eight subjects underwent all of the scheduled PET measurements. After baseline examination, quetiapine XR was administered once-daily for 8 d titrated to 300 mg/d on days 5-8, followed by 300 mg/d quetiapine IR on days 9-12. PET measurements were repeated after the last doses of quetiapine XR and IR at predicted times of peak and trough plasma concentrations. Striatal D₂ receptor occupancy was calculated using the simplified reference tissue model. Peak D₂ receptor occupancy was significantly higher with quetiapine IR than XR in all subjects (50 ± 4% and 32 ± 11%, respectively), consistent with lower peak plasma concentrations for the XR formulation. Trough D₂ receptor occupancy was similarly low for both formulations (IR 7 ± 7%, XR 8 ± 6%). The lower peak receptor occupancy associated with quetiapine XR may explain observed pharmacodynamic differences between the formulations. Assuming that our findings in control subjects are valid for patients with schizophrenia, the study supports the view that quetiapine, like the prototype atypical antipsychotic clozapine, may show antipsychotic effect at lower D₂ receptor occupancy than typical antipsychotics.
authors.affiliation: Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska University Hospital, Stockholm, Sweden. Magdalena.Nord@ki.se
authors.forename: Magdalena
authors.initials: M
authors.lastname: Nord
authors.forename: Svante
authors.initials: S
authors.lastname: Nyberg
authors.forename: Jacob
authors.initials: J
authors.lastname: Brogren
authors.forename: Aurelija
authors.initials: A
authors.lastname: Jucaite
authors.forename: Christer
authors.initials: C
authors.lastname: Halldin
authors.forename: Lars
authors.initials: L
authors.lastname: Farde
mesh_terms: D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics; D001479:Basal Ganglia / Q000000981:diagnostic imaging / Q000378:metabolism*; D001667:Binding, Competitive; D001711:Biotransformation; D002250:Carbon Radioisotopes; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D003987:Dibenzothiazepines / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D049268:Positron-Emission Tomography; D000069348:Quetiapine Fumarate; D020891:Raclopride / Q000378:metabolism; D011859:Radiography; D011869:Radioligand Assay; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D013548:Sweden; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D002250:Carbon Radioisotopes; D003692:Delayed-Action Preparations; D003987:Dibenzothiazepines; D017448:Receptors, Dopamine D2; D000069348:Quetiapine Fumarate; D020891:Raclopride; C572724:norquetiapine